

This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

A Novel Synthesis of Pyridine-2(1*H*)-thione, Pyrazolo[3,4-*b*]pyridine, Pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine, Thieno[2,3-*b*]pyridine, and Pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine Derivatives Containing a Naphthyl Moiety

Azza M. Abdel Fattah^a; Mohamed A. A. Elneairy^a; Mohamed A. M. Gad-Elkareem^b

^a Chemistry Department, Cairo University, Giza, A. R., Egypt ^b Department of Chemistry, Al-Azhar University (Assiut branch), Assiut, Egypt

To cite this Article Fattah, Azza M. Abdel , Elneairy, Mohamed A. A. and Gad-Elkareem, Mohamed A. M.(2007) 'A Novel Synthesis of Pyridine-2(1*H*)-thione, Pyrazolo[3,4-*b*]pyridine, Pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine, Thieno[2,3-*b*]pyridine, and Pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine Derivatives Containing a Naphthyl Moiety', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 182: 6, 1351 – 1364

To link to this Article: DOI: 10.1080/10426500601160991

URL: <http://dx.doi.org/10.1080/10426500601160991>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A Novel Synthesis of Pyridine-2(1*H*)-thione, Pyrazolo[3,4-*b*]pyridine, Pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine, Thieno[2,3-*b*]pyridine, and Pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine Derivatives Containing a Naphthyl Moiety

Azza M. Abdel Fattah

Mohamed A. A. Elneairy

Chemistry Department, Cairo University, Giza, A. R. of Egypt

Mohamed A. M. Gad-Elkareem

Department of Chemistry, Al-Azhar University (Assiut branch),
Assiut, Egypt

*6-Amino-4-naphthyl-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitriles 3a,b were synthesized from the reaction of naphthaldehydes 1a,b and cyanothioacetamide (2). Compounds 3a,b were taken as starting materials for the synthesis of pyrazolo[3,4-*b*]pyridine 7a,b, and 8a, Pyrido-[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine 9a,b; thieno[2,3-*b*]pyridine 16a-d, 18a,b, 21a-d, 24a,b, and 25a; and pyrido[3,2:4,5]thieno[3,2-*d*]pyrimidine 17a,b derivatives through their reactions with the corresponding reagents. All structures of the newly synthesized heterocyclic compounds were established on the basis of IR, ¹H NMR, ¹³C NMR, mass spectra, and elemental analyses.*

Keywords Pyridine-2(1*H*)-thiones; pyrido[2',3':3,4]pyrazolo-[1,5-*a*]pyrimidine; pyrido[3,2:4,5]thieno[3,2-*d*]pyrimidine; thieno[2,3-*b*]pyridine

INTRODUCTION

Recently, many chemical structures containing a naphthyl moiety were reported to exhibit diverse biological and pharmaceutical activities such as anticonvulsant,¹ antimicrobial,^{1,2} anticancer,^{3,4} anti-allergic,⁵ antiobesity,⁶ and antidiabetic⁶ agents. Moreover, 3,5-dicyanopyridines were reported to have antiproliferative activity on human cancer cell lines,⁷ pyridine-3-carbonitriles were used as


Received October 5, 2006; accepted November 18, 2006.

Address correspondence to Mohamed A. A. Elneairy, Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt. E-mail: elneairy65@yahoo.com

cardiotonic agents,^{8,9} and pyridine-2(1*H*)-thiones were reported to have antiviral¹⁰ activity. Furthermore, pyrazolo[3,4-*b*]-pyridines were used as antimalarial,¹¹ antiproliferative,¹² antimicrobial,¹³ antiviral,¹⁴ and inhibitors of cyclin-dependent kinases,¹⁵ A1-adenosine receptor ligands.¹⁶ On the other hand, thieno[2,3-*b*]pyridines were reported to have antimicrobial,¹⁷ antiviral,^{10,18} and anti-inflammatory¹⁹ activities. Also pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidines revealed anti-proliferative²⁰ activity. In addition, pyrido[3',2':4,5]thieno[3,2-*d*]-pyrimidines are used as anti-allergic,²¹ antiprotozoals,²² anti-anaphylactic,²³ and antimicrobial¹⁷ agents. In view of these reports and as a continuation of our research program in the chemistry of pyridines,^{24–33} we report the synthesis of additional new numbers of these derivatives that are required in medicinal chemistry programs.

RESULTS AND DISCUSSION

The present work reports a possible route to the synthesis of 6-amino-3,5-dicyano-4-naphthylpyridine-2(1*H*)-thiones **3a,b** as starting materials. It has been found that 1-naphthaldehyde (**1a**) reacted with 2-cyanoethanethioamide (**2a**) in a 1:2 molar ratio in ethanolic piperidine solution under reflux to give the corresponding 6-amino-4-(1-naphthyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**3a**). The structure of **3a** was established via its elemental analysis, IR, and ¹H NMR spectra. The IR spectrum of **3a** revealed NH₂ and NH groups at 3450, 3356, and 3302 cm⁻¹ and the CN group at 2214 cm⁻¹, while its ¹H NMR spectrum indicated signals at δ = 7.47–8.08 (m, 7H, Ar-H), 8.12 (s, 2H, NH₂), and 13.13 (br, 1H, NH) (cf. Experimental Section and Scheme 1).



SCHEME 1

Similarly, 2-naphthaldehyde (**1b**) reacted with 2-cyanoethanethioamide (**2a**) in a 1:2 molar ratio under the same reaction


conditions to give the corresponding 6-amino-4-(2-naphthyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**3b**). The structure of **3b** was established via its elemental analysis, IR spectra (cf. Experimental Section and Scheme 1).

The structure **3a,b** was elucidated via the synthesis by other routes. The reaction of **2a** with **1a,b** gave thiocarboxamidocinnamionitrile derivatives **4a,b**,³⁰ which further reacted with another molecule of **2a** to give **3a,b**. Condensation of malononitrile (**2b**) with **1a,b**, followed by the reaction with **2a**, afforded **3a,b**. Compounds **3a,b** that were prepared by these two routes were found completely identical in all aspects with **3a,b**, which were previously prepared (cf. Scheme 1).

It was found that compound **3a,b** reacted with methyl iodide to afford the corresponding 2-amino-6-(methylthio)-4-(naphthyl)pyridine-3,5-dicarbonitrile derivatives **5a,b**. Compound **5a** reacted with hydrazine hydrate to give a sulfur-free compound corresponding to 3,6-diamino-4-(1-naphthyl)-1*H*-pyrazolo[3,4-*b*]pyridine-5-carbonitrile (**7a**). The latter reaction product could be formed via the addition of a hydrazino group of **6a** to the nitrile function. The IR spectrum of **7a** showed the new amino group. Moreover, its mass spectrum gave $m/e = 300$, which corresponds to the molecular weight of compound **7a**. In the same manner compound **5b** reacted with hydrazine hydrate to give the corresponding 3,6-diamino-4-(2-naphthyl)-1*H*-pyrazolo[3,4-*b*]pyridine-5-carbonitrile (**7b**). Compound **7b** could be confirmed based on the elemental analysis and spectral data as **7a** (cf. Experimental Section and Scheme 2).

Condensation of **7a** with one mole of Dimethylformamide-dimethylacetal (DMF-DMA) in dry dioxan afforded 6-amino-3-{[(*N,N*-dimethylamino)methylene]amino}-1*H*-pyrazolo[3,4-*b*]pyridine derivative **8a** (cf. Scheme 2). The IR spectrum of **8a** showed the band at 3424, 3333, and 3216 cm^{-1} , which corresponds to the NH group at the pyrazole ring and NH_2 on the pyridine ring. Its ^1H NMR spectrum revealed signals at δ 3.09 (s, 3H, CH_3 , $\text{N}(\text{CH}_3)_2$), 3.19 (s, 3H, CH_3 , $\text{N}(\text{CH}_3)_2$), 7.32–7.63 (m, 7H, Ar–H), 8.04 (s, 2H, NH_2), 8.65 (s, 1H, $\text{N}=\text{CH}$), and 12.56 (s, 1H, NH). Further elucidation of the structure of **8a** was achieved via its reaction with active methylene compounds such as malononitrile (**2b**) and ethyl cyanoacetate (**2c**). Compound **8a** reacted with malononitrile (**2b**) to give the corresponding 4,8-diamino-10-(1-naphthyl)-pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine-3,9-dicarbonitrile (**9a**). The IR spectrum of **9a** showed the new amino group on the pyrimidine ring in addition to the amino group on the pyridine ring.


The ^1H NMR spectrum of **9a** showed the signals corresponding to the amino groups. Compound **8a** reacted with ethyl cyanoacetate (**2c**) to give the corresponding ethyl 4,8-diamino-9-cyano-10-(1-



SCHEME 2

naphthyl)Pyrido-[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine-3-carboxylate (**9b**). Compound **9b** was confirmed based on elemental analysis and spectral data.

It has been found that **5a** reacted with DMF-DMA to give the formamidine derivative **10**. Its IR spectrum showed the absence of the amino groups. The ^1H NMR spectrum of **10** revealed signals for $\text{N}(\text{CH}_3)_2$ and $\text{N}=\text{CH}$ protons and the absence of any signal attributed to the NH_2 protons. The reaction of **10** with hydrazine hydrate did not give the expected product **13**, but gave compound **7a**. The formation of **7a** in this




SCHEME 3

reaction is assumed to proceed via the first formation of the non-isolable hydrazino derivative **11**, which would then cyclize via an addition to the nitrile function at position-3 with the *N,N*-dimethylaminomethylene exchange of the hydrazino at position-6 under the applied reaction conditions leading to regeneration of the amino group^{27,34} at that position, and hence the formation of **7a** (cf. Experimental Section and Scheme 2). The structure of **3a,b** was confirmed via the reaction of **3a,b** with halogenated compounds such as ethyl chloroacetate (**14a**) and chloroacetamide (**14b**) (cf. Scheme 3). Thus, it was found that compound **3a** reacted with ethyl chloroacetate (**14a**) in methanolic sodium methoxide solution to yield the corresponding ethyl [6-amino-3,5-dicyano-4-(1-naphthyl)pyridin-2-yl]thioacetate (**15a**) via dehydrochlorination. The structure of **15a** was confirmed by elemental analysis and spectral data. The IR spectrum of **15a** showed the presence of absorption bands due to CN, NH₂ and ester CO functional groups (cf. Scheme 3 and Experimental Section). In a similar manner, compound **3a** reacted with **14b** to afford the corresponding 2-[6-amino-3,5-dicyano-4-(1-naphthyl)pyridin-2-yl]thioacetamide (**15c**). Compound **3b** reacted with each of **14a,b** to give the corresponding [6-amino-3,5-dicyano-4-(2-naphthyl)pyridin-2-yl]thio derivatives **15b,d**. The structures of **15a-d** were further elucidated via their cyclization to the corresponding thieno[2,3-*b*]pyridine derivatives **16a-d** upon boiling in

ethanolic potassium hydroxide solution. The structures of **16a–d** were inferred from analyses, spectral data, and chemical transformations. The IR spectra of compounds **16a–d** showed the presence of the absorption bands of the new NH_2 group (cf. Scheme 3 and Experimental Section).

Compounds **16c,d** reacted with formic acid to give the corresponding pyrido[2', 3':5,4]thieno[3,2-*d*]pyrimidine derivatives **17a,b**. The structure of compounds **17a,b** was confirmed from elemental analyses and spectral data. Reaction of compounds **15a,b** with hydrazine hydrate gave compounds **7a,b** and not the expected acid hydrazide products **18a,b**. Compounds **18a,b** were prepared via the reaction of **16a,b** with hydrazine hydrate. The elemental analyses, IR, ^1H NMR, ^{13}C NMR and mass spectra of **18a,b** were found in good agreement with the assigned structures. The mass spectrum of **18a** indicated the M^+ at m/z 374 (22.3%) and the base peak at m/z 343 (100%), which correspond to M^+ (374)– NHNH_2 (31) (cf. Scheme 3 and Experimental Section).

Furthermore, **3a** reacted with each of ω -bromoacetophenone derivatives **19a,b** in ethanol/piperidine solution under reflux to afford the corresponding thieno[2,3-*b*]pyridine derivatives **21a,b**, respectively (cf. Scheme 4). Compounds **21a,b** were formed via the non-isolable intermediates **20a,b**. The other analogue **3b** reacted with **19a,b** under the same reaction conditions to give the corresponding thieno[2,3-*b*]pyridine



SCHEME 4

derivatives **21c,d** through the non-isolable intermediates **20c,d**. Structures of **21a-d** were elucidated on the basis of IR, ^1H NMR and elemental analyses data (cf. Scheme 4 and Experimental Section).

Compounds **3a,b** reacted with chloroacetone (**22a**) in methanolic sodium methoxide solution at room temperature to afford the corresponding thieno[2,3-*b*]pyridine derivatives **24a,b** through the non-isolable intermediates **23a,b**. The reaction seemed to proceed through dehydrochlorination to give the non-isolable intermediates **23a,b**, which underwent cyclization *via* addition of the methine or a methylene group to the nitrile function. Elemental analyses and spectral data were the basis of which the structures of **24a,b** were established. Moreover, compounds **24a,b** were authenticated via the reaction of each of **3a,b** with α -chloroacetylacetone (**22b**) via the intermediacy of each of the non-isolable **23c,d**. The non-isolable intermediates **23c,d** are assumed to be cyclized to give the corresponding non-isolable 3-imino derivatives that hydrolyzed readily with liberation of one molecule of acetic acid under the applied reaction conditions to afford the final isolable **24a,b**. On the other hand, compound **3a** reacted with chloroacetonitrile to give the corresponding thieno[2,3-*b*]pyridine derivative **25**. Its structure was confirmed on the basis of elemental analysis and spectral data (cf. Scheme 4 and Experimental data).

EXPERIMENTAL

Melting points were measured with a Gallenkamp apparatus and are uncorrected. IR spectra from KBr discs were recorded on a Bruker Vector 22 FT-IR spectrophotometer. ^1H and ^{13}C NMR spectra were determined in DMSO- d_6 and CDCl_3 at 300 MHz on a Varian Mercury VX spectrometer using TMS as an internal standard. Chemical shifts are expressed as δ or ppm. Mass spectra were recorded on a GCMS-QP 1000 EX spectrometer at 70 eV. Elemental analyses were carried out at the Microanalytical Center of Cairo University, Giza, Egypt.

Compounds **4a,b**³⁰ were prepared according to the literature procedure.

Synthesis of 6-Amino-4-(naphthyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitriles **3a,b**:

General Procedures

Method A

An equimolecular amount of arylidine **4a,b** (0.238 g, 1.0 mmole), cyanoethanethioamide (**2a**) (0.1 g, 1.0 mmole) and piperidine (0.5 mL)

TABLE I Elemental Analyses of the Newly Synthesized Compounds

Compound No.	Solvent of Cry. Yield %	Color M.P., °C	Mol. Formula Mol. wt	% Analysis Calcd./ Found				
				C	H	N	S	Cl
3a	Ethanol	Yellow	C ₁₇ H ₁₀ N ₄ S	67.54	3.31	18.54	10.59	—
	65	294–296	302	67.30	3.30	18.40	10.50	—
3b	Ethanol	Yellow	C ₁₇ H ₁₀ N ₄ S	67.54	3.31	18.54	10.59	—
	60	276–278	302	67.40	3.20	18.30	10.40	—
5a	Ethanol	Yellow	C ₁₈ H ₁₂ N ₄ S	68.35	3.79	17.72	10.12	—
	55	264–268	316	68.30	3.60	17.60	10.20	—
5b	Ethanol	White	C ₁₈ H ₁₂ N ₄ S	68.35	3.79	17.72	10.12	—
	68	254–256	316	68.20	3.70	17.60	10.10	—
7a	Ethanol	Yellow	C ₁₇ H ₁₂ N ₆	67.54	4.67	27.80	—	—
	65	296–298	300	67.40	4.50	27.70	—	—
7b	Ethanol	Yellow	C ₁₇ H ₁₂ N ₆	67.54	4.67	27.80	—	—
	75	278–280	300	67.30	4.50	27.60	—	—
8a	Dioxane	Yellow	C ₂₀ H ₁₇ N ₇	67.61	4.79	27.61	—	—
	67	308	355	67.50	4.70	27.60	—	—
9a	Ethanol	Red	C ₂₁ H ₁₂ N ₈	67.02	3.19	29.70	—	—
	70	354–356	376	67.10	3.10	29.70	—	—
9b	Acetic acid	Yellow	C ₂₁ H ₁₂ N ₈	65.25	4.02	23.17	—	—
	64	320	423	65.20	3.90	23.10	—	—
10	Dioxane	Yellow	C ₂₁ H ₁₇ N ₅ S	67.92	4.58	18.87	8.63	—
	70	284–286	371	67.80	4.50	18.70	8.50	—
15a	Ethanol	Yellow	C ₂₁ H ₁₆ N ₄ O ₂ S	64.94	4.12	14.43	8.24	—
	60	202–204	388	64.80	4.10	14.30	8.20	—
15b	Ethanol	Yellow	C ₂₁ H ₁₆ N ₄ O ₂ S	64.94	4.12	14.43	8.24	—
	65	210	388	64.70	4.10	14.20	8.10	—
15c	Ethanol	Yellow	C ₁₉ H ₁₃ N ₅ OS	63.51	3.62	19.49	8.91	—
	64	264	359	63.40	3.50	19.30	8.80	—
15d	Ethanol	Yellow	C ₁₉ H ₁₃ N ₅ OS	63.51	3.62	19.49	8.91	—
	55	220	359	63.30	3.50	19.30	8.80	—
16a	Ethanol	White	C ₂₁ H ₁₆ N ₄ O ₂ S	64.94	4.12	14.43	8.24	—
	68	310–312	388	64.70	4.00	14.20	8.20	—
16b	Ethanol	Yellow	C ₂₁ H ₁₆ N ₄ O ₂ S	64.94	4.12	14.43	8.24	—
	55	>300	388	64.70	4.10	14.20	8.10	—
16c	Ethanol	Yellow	C ₁₉ H ₁₃ N ₅ OS	63.51	3.62	19.49	8.91	—
	64	310	359	63.40	3.50	19.30	8.80	—
16d	Ethanol	Yellow	C ₁₉ H ₁₃ N ₅ OS	63.51	3.62	19.49	8.91	—
	54	272–274	359	63.40	3.40	19.40	8.80	—
17a	Ethanol	Yellow	C ₂₀ H ₁₁ N ₅ OS	65.04	2.98	18.97	8.67	—
	70	200	369	65.10	2.80	18.80	8.60	—
17b	Ethanol	Yellow	C ₂₀ H ₁₁ N ₅ OS	65.04	2.98	18.97	8.67	—
	50	>300	369	64.90	2.90	18.80	8.60	—
18a	Ethanol	Yellow	C ₁₉ H ₁₄ N ₆ OS	60.96	3.74	22.46	8.56	—
	65	278	374	60.80	3.60	22.40	8.40	—
18b	Ethanol	Yellow	C ₁₉ H ₁₄ N ₆ OS	60.96	3.74	22.46	8.56	—
	60	200	374	60.80	3.60	22.30	8.40	—

(Continued on next page)

TABLE I Elemental Analyses of the Newly Synthesized Compounds (Continued)

Compound No.	Solvent of Cry. Yield %	Color M.P., °C	Mol. Formula Mol. wt	% Analysis Calcd./ Found				
				C	H	N	S	Cl
21a	Ethanol	Yellow	C ₂₅ H ₁₆ N ₄ OS	71.42	3.80	13.33	7.61	—
	65	322–324	420	71.20	3.70	13.20	7.50	—
21b	Ethanol	Yellow	C ₂₅ H ₁₅ N ₄ OSC	66.00	3.30	12.32	7.04	7.8
	55	344–346	454.5	65.90	3.20	12.30	6.80	7.8
21c	Ethanol	Orange	C ₂₅ H ₁₆ N ₄ OS	71.42	3.80	13.33	7.61	—
	60	318–320	420	71.20	3.70	13.20	7.50	—
21d	Ethanol	Orange	C ₂₅ H ₁₅ N ₄ OSC	66.00	3.30	12.32	7.04	7.8
	68	330–332	454.5	66.10	3.20	12.30	6.80	7.8
24a	Ethanol	Yellow	C ₂₀ H ₁₄ N ₄ OS	67.03	3.91	15.64	8.94	—
	55	320–322	358	67.10	4.10	15.50	8.80	—
24b	Ethanol	Yellow	C ₂₀ H ₁₄ N ₄ OS	67.03	3.91	15.64	8.94	—
	65	318	358	67.10	4.10	15.50	8.80	—
25	DMF	Green	C ₁₉ H ₁₁ N ₅ S	66.86	3.23	20.53	9.38	—
	68	286	341	66.70	3.20	20.40	9.30	—

in ethanol (30 mL) was heated under reflux for 5 h. The excess of the ethanol was evaporated by vacuum. The solid obtained was collected by filtration and crystallized from ethanol to give **3a,b**, respectively (cf. Tables I and II).

Method B

A mixture of 1- or 2-naphthalaldehyde (**1a,b**) (0.156 g, 1.0 mmole), cyanoethanethioamide (**2a**) (0.2 g, 2.0 mmole), and piperidine (0.5 mL) in ethanol (30 mL) was heated under reflux for 5 h. The excess of the ethanol was evaporated by vacuum. The solid obtained was collected by filtration and crystallized from ethanol to give **3a,b**, respectively (cf. Tables I and II).

Method C

A mixture of 1- or 2-naphthalaldehyde (**1a,b**) (0.156 g, 1.0 mmole), cyanoethanethioamide (**2a**) (0.1 g, 1 mmole), malononitrile (**2b**) (0.066 g, 1.0 mmole), and piperidine (0.5 mL) in ethanol (30 mL) was heated under reflux for 5 h. The excess of ethanol was evaporated by vacuum. The solids obtained were collected by filtration and crystallized from ethanol to give **3a,b**, respectively (cf. Tables I and II).

TABLE II Spectral Data of the Newly Synthesized Compounds

Compound No.	Spectral data, IR (cm ⁻¹), ¹ H NMR, ¹³ C NMR and MS
3a	IR: 3450, 3356, 3302 (NH ₂ and NH) and 2214 (CN); ¹ H NMR: (DMSO-d ₆)δ 7.47–8.08 (m, 7H, Ar-H), 8.12 (s, 2H, NH ₂ , and 13.13 (br., 1H, NH); ¹³ C NMR (DMSO-d ₆)δ 82.94, 103.82, 114.15, 116.05, 124.36, 125.31, 125.79, 126.55, 127.24, 128.41, 129.15, 130.0, 132.04, 132.87, 154.43, 158.02 and 179.25.
3b	IR: 3442, 3365, 3308 (NH ₂ and NH) and 2216 (CN).
5a	IR: 3315, 3193 (NH ₂) and 2215 (CN); ¹ H NMR: (DMSO-d ₆)δ 2.75 (s, 3H, SCH ₃), 7.38–7.88 (m, 7H, Ar-H), 8.11 (s, 2H, NH ₂).
5b	IR: 3320, 3195 (NH ₂) and 2214 (CN).
7a	IR: 3473, 3354, 3300, 3155 (two NH ₂ and NH) and 2213 (CN); ¹ H NMR: (DMSO-d ₆)δ 6.54 (s, 2H, NH ₂), 7.42–7.75 (m, 7H, Ar-H), 8.24 (s, 2H, NH ₂) and 12.18 (s, 1H, NH); MS: m/z 300 (33%), 301 (100%).
7b	IR: 3460, 3355, 3306, 3150 (two NH ₂ and NH) and 2215 (CN); ¹ H NMR: (DMSO-d ₆)δ 6.79 (s, 2H, NH ₂), 7.60–8.08 (m, 7H, Ar-H), 8.14 (s, 2H, NH ₂) and 11.91 (s, 1H, NH).
8	IR: 3424, 3333 and 3216 (NH ₂ and NH) and 2214 (CN); ¹ H NMR: (DMSO-d ₆)δ 3.09 (s, 3H, CH ₃ , N(CH ₃) ₂), 3.19 (s, 3H, CH ₃ , N(CH ₃) ₂), 7.32–7.63 (m, 7H, Ar-H), 8.04 (s, 2H, NH ₂), 8.65 (s, 1H, N=CH) and 12.56 (s, 1H, NH); ¹³ C NMR (DMSO-d ₆)δ 32.39, 34.37, 105.13, 117.49, 124.79, 125.22, 125, 64, 126.14, 126.82, 127.79, 128.50, 129.85, 130.92, 132.55, 150.19, 152.40, 153.04, 155.94, 156.01 and 162.47.
9a	IR: 3427, 3391, 3310, 3289 (two NH ₂), 2214 (CN); ¹ H NMR: (DMSO-d ₆)δ 8.04–8.96 (m, 7H, Ar-H), 9.01 (s, 2H, NH ₂), 9.66 (s, 1H, N=CH) and 9.98 (s, 2H, NH ₂); ¹³ C NMR (DMSO-d ₆)δ 78.86, 100.46, 101.93, 114.78, 116.68, 118.49, 118.80, 125.15, 125.92, 128.19, 129.28, 130.18, 131.87, 132.81, 144.08, 148.78, 152.64, 159.40 and 164.42.
9b	IR: 3400, 3336, 3273, 3235, (two NH ₂); 2218 (CN) and 1694 (ester CO); ¹ H NMR: (DMSO-d ₆)δ 1.23–1.27 (t, J = 7.5 Hz, 3H, CH ₂ CH ₃), 4.26–4.28 (q, J = 7.5 Hz, 2H, CH ₂ CH ₃), 7.39–8.13 (m, 9H, Ar-H and NH ₂), 8.38 (s, 2H, NH ₂) and 8.83 (s, 1H, CH).
10	IR: 2221 (CN); ¹ H NMR: (DMSO-d ₆)δ 2.82 (s, 3H, SCH ₃), 3.06 (s, 3H, CH ₃ , N(CH ₃) ₂), 3.11 (s, 3H, CH ₃ , N(CH ₃) ₂), 7.42–7.83 (m, 7H, Ar-H) and 8.55 (s, 1H, N=CH).
15a	IR: 3479, 3325 (NH ₂), 2214 (CN) and 1743 (ester CO).
15b	IR: 3475, 3320, (NH ₂), 2218 (CN), and 1745 (ester CO); ¹ H NMR: (DMSO-d ₆)δ 1.21–1.26 (t, J = 7.2 Hz, 3H, CH ₂ CH ₃), 4.13–4.20 (q, J = 7.2 Hz, 2H, CH ₂ CH ₃), 4.22 (s, 2H, SCH ₂), 7.61–8.09 (m, 7H, Ar-H), and 8.15 (s, 2H, NH ₂).
15c	IR: 3450, 3417, 3294, 3178 (two NH ₂), 2217 (CN) and 1651 (amidic CO).
15d	IR: 3452, 3402, 3332, 3224 (two NH ₂), 2214 (CN) and 1643 (amidic CO).
16a	IR: 3478, 3367, 3294, 3198 (two NH ₂), 2218 (CN) and 1690 (CO-ester with H-bond).
16b	IR: 3400, 3356, 3273, 3178 (two NH ₂), 2216 (CN) and 1694 (CO-ester with H-bond); MS: m/z 388 (53.2%), 316 (100%).

(Continued on next page)

TABLE II Spectral Data of the Newly Synthesized Compounds (Continued)

Compound No.	Spectral data, IR (cm ⁻¹), ¹ H NMR & ¹³ C NMR and MS
16c	IR: 3479, 3425, 3379, 3325, 3325, 3209 (three NH ₂), 2214 (CN) and 1635 (amidic-CO with H-bond).
16d	IR: 3490, 3402, 3332, 3224 (three NH ₂), 2214 (CN) and 1643 (amidic-CO); ¹ H NMR: (DMSO-d ₆) δ 5.58 (s, 2H, NH ₂), 6.97 (s, 2H, NH ₂), 7.33 (s, 2H, NH ₂) and 7.57–8.12 (m, 7H, Ar-H).
17a	IR: 3490, 3332, 3200 (NH ₂ and NH), 2214 (CN) and 1658 (CO); ¹ H NMR: (DMSO-d ₆) δ 7.55–7.67 (m, 7H, Ar-H), 8.05 (s, 2H, NH ₂), 8.11 (s, 1H, CH) and 8.14 (s, 1H, NH).
17b	IR: 3495, 3336, 3204 (NH ₂ and NH), 2214 (CN) and 1651(CO).
18a	IR: 3463, 3402, 3301, 3186 (three NH ₂ and NH), 2214 (CN) and 1630(CO); ¹ H NMR: (DMSO-d ₆) δ 4.32 (br, 2H, NH ₂), 5.24 (br, 2H, NH ₂), 7.36–7.74 (m, 7H, A-rH), 8.19 (s, 2H, NH ₂) and 8.84 (s, 1H, NH); ¹³ C NMR: (DMSO-d ₆) δ 90.66, 115.46, 124.34, 125.42, 126.44, 126.75, 127.48, 128.50, 129.89, 130.86, 132.81, 145.42, 145.70, 150.10, 158.41, 188.71.
18b	IR: 34643, 3400, 3309, 3196 (three NH ₂ and NH), 2214 (CN) and 1635(CO).
21a	IR: 3467, 3334, 3220, 3178 (two NH ₂), 2214 (CN) and 1650 (CO); ¹ H NMR: (DMSO-d ₆) δ 5.55 (br, 2H, NH ₂), 6.68–7.47 (m, 14H, A-rH and NH ₂); ¹³ C NMR: (DMSO-d ₆) δ 91.58, 99.65, 113.34, 114.99, 124.18, 125.60, 126.40, 126.81, 128.27, 129.52, 130.22, 132.98, 140.78, 150.64, 152.00, 159.24, 166.17, 183.09 and 187.50; MS: m/z 420 (100%), 77 (48.1%).
21b	IR: 3467, 3334, 3220, 3178 (two NH ₂), 2219 (CN) and 1650 (CO).
21c	IR: 3467, 3334, 3220, 3178 (two NH ₂), 2217(CN) and 1654 (CO).
21d	IR: 3467, 3334, 3220, 3178 (two NH ₂), 2214(CN) and 1656 (CO); ¹ H NMR: (DMSO-d ₆) δ 6.75 (br, 2H, NH ₂), 7.56–8.17 (m, 11H, Ar-H) and 8.21 (s, 2H, NH ₂).
24a	IR: 3437, 3324, 3210, 3188 (two NH ₂), 2218(CN) and 1646 (CO with H-bond); ¹ H NMR: (DMSO-d ₆) δ 2.21 (s, 3H, CH ₃), 5.95 (br, 2H, NH ₂), 7.38–8.12 (m, 7H, Ar-H) and 8.21 (s, 2H, NH ₂).
24b	IR: 3447, 3354, 3230, 3198 (two NH ₂), 2216(CN) and 1643 (CO With H-bond).
25	IR: 3464, 3229, 3221, 3163 (two NH ₂), 2193 (CN); ¹ H NMR: (DMSO-d ₆) δ 4.96 (s, 2H, NH ₂), 7.40–8.13 (m, 7H, Ar-H) and 8.23 (s, 2H, NH ₂).

Synthesis of 2-Amino-6-(methylthio)-4-(naphthyl)pyridine-3,5-dicarbonitriles **5a, b**

A solution of each of **3a,b** (0.302 g, 1.0 mmole) and methyl iodide (0.213 mL, 1.5 mmole) in sodium methoxide (prepared from 0.01 mol sodium metal in 30 mL of methanol) was heated under reflux for 2 h and then cooled, poured onto ice-cold water, and acidified with hydrochloric acid. The solid products were collected by filtration, washed with water, and crystallized from ethanol to give **5a,b**, respectively (cf. Tables I and II).

Reactions with Hydrazine Hydrate: General Procedure

A solution of the appropriate **5a**, **b** or **10** (0.316 or 0.371 g, 1.0 mmole) in hydrazine hydrate (15 mL) and ethanol (20 mL) was heated under reflux for 5 h. The solid products formed were collected by filtration and crystallized from the proper solvent to give **7a,b** and **7a**, respectively (cf. Tables I and II).

Reactions of **5a** and/or **7a** with DMF-DMA

A mixture of the appropriate **5a** or **7a** (0.316 or 0.3 g, 1.0 mmole) and DMF-DMA (1.692 mg, 1.2 mmole) in dry dioxane (30 mL) was heated under reflux for 3 h. The solids obtained after cooling were collected by filtration and crystallized from dioxane to give **10** and **8a**, respectively (cf. Tables I and II).

Synthesis of 4,8-Diamino-10-(1-naphthyl)pyrido[2',3':3,4]-pyrazolo[1,5-*a*]pyrimidine-3,9-dicarbonitrile (**9a**) and Ethyl 4,8-Diamino-9-cyano-10-(1-naphthyl)pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine-3-carboxylate (**9b**)

A mixture of compound **8a** (0.355 g, 1.0 mmole) and either malononitrile (**2b**) or ethyl cyanoacetate (**2c**) (0.066 g or 0.113 ml, 1.0 mmole) in ethanol (30 mL) containing 0.5 mL of triethylamine, as a catalyst, was heated under reflux for 5 h. The solid products formed were collected by filtration and crystallized from the proper solvent to give **9a,b**, respectively (cf. Tables I and II).

Reactions of **3a,b** with Halogen-Containing Compounds

General Procedure

A solution of **3a,b** (0.302 g, 1.0 mmole) and the appropriate **14a,b**, **19a,b**, **22a,b** and/or chloroacetonitrile (1.0 mmole) in sodium methoxide (prepared from 0.023 g, 1.0 mmole, of sodium metal in 30 mL methanol) was heated under reflux for 4 h. The mixture was cooled, poured onto ice-cold water, and acidified with hydrochloric acid. The solid products were collected by filtration, washed with water, and crystallized from the proper solvent to give **15a-d**, **21a-d**, **24a,b**, and **25**, respectively (cf. Tables I and II).

Cyclization of **15a-d**

A solution of the appropriate **15a,b** (0.388 g, 1.0 mmole) in ethanol (30 mL) and potassium hydroxide (0.112 g, 2.0 mmole) was heated under

reflux for 4 h. The mixture was cooled, poured on to ice-cold water, and acidified with hydrochloric acid. The solid products were collected by filtration, washed with water, and crystallized from the proper solvent to give **16a–d**, respectively (cf. Tables I and II).

Synthesis of 7-Amino-9-(naphthyl)-4-oxo-3,4-dihydropyrido-[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carbonitriles **17a,b**

A solution of **16c,d** (0.359 g, 1.0 mmole) in formic acid (20 mL) was heated under reflux for 5 h. The excess solvent was evaporated by vacuum. The solids obtained were collected by filtration and crystallized from ethanol to give **17a,b** (cf. Tables I and II).

Synthesis of 3,6-Diamino-5-cyano-4-(naphthyl)thieno [2,3-*b*]pyridine-2-carbohydrazides **18a,b**

A solution of **16a,b** (0.388 g, 1.0 mmole) in hydrazine hydrate (20 mL) and ethanol (20 mL) was heated under reflux for 3 h. The solid products obtained after cooling were collected by filtration and crystallized from ethanol to give **18a,b** (cf. Tables I and II).

REFERENCES

- [1] A. Karakurt, S. Dalkara, M. Özalp, S. Özbey, E. Kendi, and J. P. Stables, *Eur. J. Med. Chem.*, **36**, 421 (2001).
- [2] D. Azarifar and M. Shaebozadeh, *Molecules*, **7**, 885 (2002).
- [3] A. Duran, H. N. Dogan, and S. Rollas, *IL Farmaco*, **57**, 559 (2002).
- [4] C. Dell'Erba, B. Chiavarina, C. Fenoglio, G. Petrillo, C. Cordazzo, E. Boncompagni, et al., *Pharmacological Research*, **52**, 271 (2005).
- [5] T. K. Venkatachalam, S. Qazi, P. Samuel, and F. M. Uckum, *Bioorg. Med. Chem.*, **11**, 1095 (2003).
- [6] P. S. Kumar and P. V. Bharatam, *Arkivoc*, **13**, 67 (2005).
- [7] M. T. Cocco, C. Congiu, V. Lilliu, and V. Onnis, *Eur. J. Med. Chem.*, **40**, 1365 (2005).
- [8] A. A. Bekhit and A. M. Baraka, *Eur. J. Med. Chem.*, **40**, 1405 (2005).
- [9] A. Krauze, R. Vitoliņa, V. Garaliene, L. Stīle, V. Kluša, and G. Duburs, *Eur. J. Med. Chem.*, **40**, 1163 (2005).
- [10] F. A. Attaby, M. A. Ali, A. H. H. Elghandour, and Y. M. Ibrahim, *Phosphorus, Sulfur, and Silicon*, **181**, 1 (2006).
- [11] C. M. S. Menezes, C. M. R. Sant'Anna, C. R. Rodrigues, and E. J. Barreiro, *J. Mol. Struct. (Thermochem.)*, **579**, 31 (2002).
- [12] K. Poreba, A. Oplski, and J. Wietrzyk, *Acta. Pol. Pharm.*, **59**, 215 (2002).
- [13] F. E. Goda, A. A. M. Abdel-Aziz, and O. A. Attet, *Bioorg. Med. Chem.*, **12**, 1845 (2004).
- [14] F. A. Attaby, A. H. H. Elghandour, M. A. Ali, and Y. M. Ibrahim, *Phosphorous, Sulfur, and Silicon*, **181**, 1087 (2006).
- [15] R. N. Misra, H. Y. Xiao, D. B. Rawlins, W. Sham, K. A. Keller, J. G. Mulheron, et al., *Bioorg. Med. Chem. Lett.*, **13**, 2405 (2003).

- [16] S. Schenone, O. Bruno, P. Fossa, A. Ranise, G. Menozzi, L. Mosti, et al., *Bioorg. Med. Chem. Lett.*, **11**, 2529 (2001).
- [17] A. E. Abdel-Rahman, E. A. Bakhite, and E. A. Al-Tafi, *Pharmazie*, **58**, 372 (2003).
- [18] M. E. Schnute, M. M. Cudaly, R. J. Brideau, F. L. Homa, T. A. Hopkins, M. L. Knechtel, et al., *J. Med. Chem.*, **48**, 5794 (2005).
- [19] G. P. Moloney, *Molecules*, **6**, M203 (2001).
- [20] K. Poreba, A. Oplski, J. Wietrzyk, and M. Kowalska, *Arch. Pharmazie*, **334**, 219 (2001).
- [21] J. M. Quintela, C. Prinador, C. Veiga, L. Gonzales, L. M. Botana, A. Alfonso, et al., *Bioorg. Med. Chem.*, **6**, 1911 (1998).
- [22] J. M. Quintela, C. Prinador, L. Gonzales, R. Iglesias, A. Parama, F. Alvares, et al., *Eur. J. Med. Chem.*, **38**, 265 (2003).
- [23] G. Wagner, S. Leistner, H. Vieweg, U. Krasselt, and J. Prantz, *Pharmazie*, **48**, 342 (1993).
- [24] M. A. A. Elneairy, M. A. M. Gad-Elkareem, and A. M. Abd El-Fattah, *Phosphorus, Sulfur, and Silicon*, **181**, 1451 (2006).
- [25] M. A. M. Gad-Elkareem, A. M. Abd El-Fattah, and M. A. A. Elneairy, *Phosphorus, Sulfur, and Silicon*, **181**, 891 (2006).
- [26] M. A. M. Gad-Elkareem, M. A. A. Elneairy, and A. M. Taha, *Heteroatom Chemistry*, **18**, in press (2007).
- [27] M. A. A. Elneairy, M. A. M. Gad-Elkareem, and A. M. Taha, *Heteroatom Chemistry*, **18**, in press (2007).
- [28] M. A. A. Elneairy, M. A. M. Gad-Elkareem, and A. M. Taha, *J. Sulfur Chem.*, **26**, 381 (2005).
- [29] M. A. A. Elneairy and A. M. Abdel-Fattah, *Phosphorus, Sulfur, and Silicon*, **175**, 15 (2001).
- [30] M. A. A. Elneairy, S. M. Eldin, F. A. Attaby, and A. K. K. El-Louh, *Phosphorus, Sulfur, and Silicon*, **167**, 289 (2000).
- [31] S. M. Eldin, M. A. A. Elneairy, F. A. Attaby, and A. K. K. El-Louh, *Phosphorus, Sulfur, and Silicon*, **176**, 49 (2001).
- [32] A. M. Abd El-Fattah, *Phosphorus, Sulfur, and Silicon*, **156**, 53 (2000).
- [33] M. A. M. Gad-Elkareem and A. O. Abdelhamid, *Afinidad*, **61**, 427 (2004).
- [34] V. A. Markarov, O. B. Ryabova, L. M. Alekseeva, A. S. Shashkov, and V. G. Granik, *Chem. Heterocycl. Compd.*, **39**, 238 (2003).